Comments
Loading...
TransCode Therapeutics (NASDAQ:RNAZ) Stock, Earnings Estimates, EPS, And Revenue
TransCode Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Mar 31
EPS Estimate
$-3.210
Quarterly Revenue Estimate
$300.00K
Annual Revenue
(as of Sep 30)
(as of Sep 30)
–
Analyze the earnings history of TransCode Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
TransCode Therapeutics (RNAZ) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2024-11-14 | $-5.28 | $-16.17 | 67.3 % |
| Q2 | 2024-08-14 | $-24.42 | $-19.14 | -27.6 % |
| Q1 | 2024-05-15 | $-21.45 | $-16.50 | -30.0 % |
| Q4 | 2024-04-01 | $-30.69 | $-356.40 | 91.4 % |
TransCode Therapeutics (RNAZ) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | 2024-11-14 | $0 | $300.00K | -100.0 % |
FAQ
When is TransCode Therapeutics (NASDAQ:RNAZ) reporting earnings?
TransCode Therapeutics (RNAZ) is scheduled to report earnings on March 31, 2025. The last reported earnings were for reported on November 14, 2024 for Q3.
What were the latest earnings per share (EPS) for TransCode Therapeutics (NASDAQ:RNAZ)?
The Actual EPS was $-5.28, which beat the estimate of $-16.17.
What were TransCode Therapeutics’s (NASDAQ:RNAZ) revenues?
The Actual Revenue was $0K, which missed the estimate of $300K.
Browse earnings estimates, EPS, and revenue on all stocks.